Cooley manages the global patent portfolio of Usher III Initiative, Inc., a research consortium of leading retinal and cochlear specialists established to develop treatments for Usher Syndrome Type III. Usher Syndrome is a genetic disorder that causes progressive hearing and vision loss and affects less than 0.01% of the population worldwide. Cooley’s work has resulted in the issuance of US and foreign patents covering small-molecule therapeutics showing promise as drugs useful for treating Usher Syndrome Type III.